Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Alan Rogers

Internal Medicine Tucson, AZ Medical Doctor

NPI 1821037474 CMS profile 36822

5555 E 5Th St Ste 101, Tucson, AZ 85711

Open in the dashboard

General payments

$5,132

314 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Alan Rogers of Tucson, AZ is reported in the CMS Open Payments database as having received $5,132 across 314 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $459 23
2023 General $1,505 87
2022 General $849 52
2021 General $657 44
2020 General $170 12
2019 General $1,492 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alan Rogers
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Alan Rogers were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Alan Rogers Internal Medicine median Middle half National median
2019 $1,492 $159 $48–$570 $163
2020 $170 $119 $33–$402 $114
2021 $657 $135 $37–$521 $132
2022 $849 $141 $42–$496 $149
2023 $1,505 $149 $45–$519 $160
2024 $459 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novo Nordisk Inc $623 42 payments
  2. Amgen Inc. $439 26 payments
  3. Pfizer Inc. $438 38 payments
  4. AstraZeneca Pharmaceuticals LP $424 14 payments
  5. AbbVie, Inc. $342 22 payments
  6. GlaxoSmithKline, LLC. $273 17 payments
  7. Janssen Pharmaceuticals, Inc $235 17 payments
  8. Sanofi-Aventis U.S. LLC $211 14 payments
  9. Lilly USA, LLC $207 13 payments
  10. Abbott Laboratories $188 9 payments
  11. Other $1,751 102 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $5,100 312 payments
  2. Education $32 2 payments
Products named General payments · program years 2019–2024
  1. Ozempic $366 30 payments
  2. RYBELSUS $298 24 payments
  3. Repatha $276 16 payments
  4. FASENRA $251 2 payments
  5. XARELTO $235 17 payments
  6. Otezla $202 10 payments
  7. FARXIGA $200 6 payments
  8. SHINGRIX $176 10 payments
  9. XIFAXAN $168 10 payments
  10. SYMBICORT $163 4 payments
  11. Other $5,377 352 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 120 drugs

Part D claims

5,823

Median for Internal Medicine: 777

Drug cost

$457,341

Median for Internal Medicine: $73,373

Branded share of claims

17.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 87 $99,052
Ozempic Semaglutide Brand 64 $61,815
Descovy Emtricitabine/Tenofov Alafenam Brand 14 $35,825
Xarelto Rivaroxaban Brand 24 $35,599
Mounjaro Tirzepatide Brand 28 $28,393
Farxiga Dapagliflozin Propanediol Brand 16 $28,197
Prolia Denosumab Brand 14 $24,472
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 20 $17,219
Repatha Sureclick Evolocumab Brand 20 $12,321
Myrbetriq Mirabegron Brand 13 $10,972

The 10 drugs with the highest cost, of 120 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$1,476

Medicare's payments for the services billed

Medicare patients

24

Average age 78

Services billed

69

12 women, 12 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Korlym
  • Corcept Therapeutics $35
$35 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $33
$33 16 —
Otezla
  • Amgen Inc. $32
$32 — —
Repatha
  • Amgen Inc. $32
$32 20 —
Veozah
  • Astellas Pharma US Inc $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

314 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record